The corticosteroid Fluticasone Propionate (fluticasone) and the long-acting. Adrenoceptor Agonist Formoterol Fumarate (formoterol) have been accumulated in an one-on-one, metered-dose, pressurized, aerosol inhaler for the fixing treatment of patients aged 12 years with lasting asthma.
In well planned 8- and 12-week clinical attempts in patients with asthma, twice-daily fluticasone/formoterol 100/10, 250/10 (adults and adolescents) or 500/20 (adults only) evidenced fast and sustained betterment in asthma control and lung function. Improvements attained with the set accumulation were greater than those attained with placebo or monotherapy with either of the identical various dosages of this medicine, and kindred to those signified when the individual constituents were managed through separate inhalers at the same time. The effectiveness of fluticasone/formoterol was noninferior to that of Fluticasone Propionate Formoterol Fumarate exhibited a quick onset of bronchodilation. It was by and large well tolerated and the tolerability profile of was mostly analogous to that of budesonide/formoterol.
These Fluticasone Propionate and Formoterol Fumarate Inhaler contain two accumulation ingredients, namely formoterol fumarate and fluticasone propionate, which help to the reduce swelling and excitement in the airways. It also incorporates bronchodilators that make the inhale and exhale activity simpler by relaxing the constricted airways.